Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481243 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT04481243: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT04481243 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04481243, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.
Interventions
- PROCEDURE Blood draw
- BIOLOGICAL Pneumovax 23- pneumococcal polysaccharide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2023-01-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04481243
The ClinicalTrials.gov registry entry for NCT04481243 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT04481243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04481243 about?
NCT04481243 is a clinical study titled "A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 Diabetes". The purpose of this study is to determine if children with type 1 diabetes have adequate immune response to PPSV23 vaccination and to assess factors affecting immune response.
What is the current status of trial NCT04481243?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2021-04-30. Estimated completion is 2023-01-20.
What interventions are being tested in trial NCT04481243?
The interventions under investigation include: Blood draw (PROCEDURE), Pneumovax 23- pneumococcal polysaccharide (BIOLOGICAL).
Who is sponsoring clinical trial NCT04481243?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.